Xiamen Amoytop Biotech Co Ltd Market Cap ($2.69 Billion)
Market Cap & Net Worth: Xiamen Amoytop Biotech Co Ltd (688278)
Xiamen Amoytop Biotech Co Ltd market cap. Xiamen Amoytop Biotech Co Ltd (SHG:688278) has a market capitalization of $2.69 Billion (CN¥18.41 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #5051 globally and #828 in its home market, demonstrating a 2.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xiamen Amoytop Biotech Co Ltd's stock price CN¥45.09 by its total outstanding shares 408189480 (408.19 Million). Also see Xiamen Amoytop Biotech Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Xiamen Amoytop Biotech Co Ltd Market Cap History (2020–2026)
Xiamen Amoytop Biotech Co Ltd market cap history from 2020 to 2026. Data shows growth from $2.02 Billion to $2.69 Billion (3.83% CAGR). Check Xiamen Amoytop Biotech Co Ltd stock quote for real-time trading data and today's change.
Xiamen Amoytop Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xiamen Amoytop Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Xiamen Amoytop Biotech Co Ltd annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.56x
Xiamen Amoytop Biotech Co Ltd's market cap is 1.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.30x
Xiamen Amoytop Biotech Co Ltd's market cap is 5.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.02 Billion | $793.93 Million | $116.57 Million | 2.54x | 17.29x |
| 2021 | $1.73 Billion | $1.13 Billion | $181.20 Million | 1.53x | 9.56x |
| 2022 | $2.31 Billion | $1.53 Billion | $287.02 Million | 1.52x | 8.06x |
| 2023 | $3.13 Billion | $2.10 Billion | $555.45 Million | 1.49x | 5.63x |
| 2024 | $4.38 Billion | $2.82 Billion | $827.60 Million | 1.56x | 5.30x |
Competitor Companies of 688278 by Market Capitalization
Companies near Xiamen Amoytop Biotech Co Ltd in the global market cap rankings as of November 8, 2026. Also see Xiamen Amoytop Biotech Co Ltd (688278) total assets for a full breakdown of the balance sheet.
Key companies related to Xiamen Amoytop Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Xiamen Amoytop Biotech Co Ltd (2020–2026)
Market capitalization of Xiamen Amoytop Biotech Co Ltd from 2020 to today. Between 2020 and today, Xiamen Amoytop Biotech Co Ltd's market cap moved from $2.02 Billion to $ 2.69 Billion, with a yearly change of 3.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.69 Billion | -46.12% |
| 2025 | CN¥5.00 Billion | +14.05% |
| 2024 | CN¥4.38 Billion | +40.15% |
| 2023 | CN¥3.13 Billion | +35.16% |
| 2022 | CN¥2.31 Billion | +33.49% |
| 2021 | CN¥1.73 Billion | -14.00% |
| 2020 | CN¥2.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Xiamen Amoytop Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.69 Billion USD |
| MoneyControl | $2.69 Billion USD |
| MarketWatch | $2.69 Billion USD |
| marketcap.company | $2.69 Billion USD |
| Reuters | $2.69 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xiamen Amoytop Biotech Co Ltd
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.